← Back to All Filings

Natera CEO & Director Steven Chapman Files Form 144 to Sell $526K in Common Stock Under 10b5-1 Plan

Low SignificanceOctober 1, 2026 at 9:09:25 PM UTC

Natera, Inc.

$NTRA144CIK: 0001604821

Subscribe to track NTRA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Form 144 Filing Analysis: Natera, Inc. (NASDAQ: NTRA) Insider: Steven L Chapman (Officer, Director) Proposed Sale: 1,273 shares Common Stock Estimated Value: $526,143.63 (~$413.31/share) Plan Adoption Date: March 5, 2026 Significance: Low (Pre-scheduled Rule 10b5-1 plan execution)

Comprehensive Analysis

Executive Summary

On October 1, 2026, Steven L. Chapman, Director and Officer (Chief Executive Officer) of Natera, Inc. (NASDAQ: NTRA), filed a Form 144 notice disclosing the intent to sell 1,273 shares of Common Stock through Morgan Stanley Smith Barney LLC. The aggregate market value of the shares to be sold is approximately $526,143.63, representing an estimated average price of $413.31 per share.

Transaction Details & Plan Adoption

  • Shares to Sell: 1,273 common shares
  • Gross Proceeds / Market Value: $526,143.63
  • Approximate Sale Date: October 1, 2026
  • Rule 10b5-1 Plan: The proposed sale is executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026.
  • Origin of Shares: The shares were acquired via restricted stock unit vesting on July 26, 2026 (450 shares), July 27, 2026 (615 shares), and July 31, 2026 (208 shares).

Prior Sales Within Past 3 Months

Over the preceding 90 days, Chapman has completed regular scheduled sales:

  • 09/01/2026: 1,698 shares for $545,041.02
  • 08/03/2026: 1,894 shares for $502,667.60
  • 08/03/2026: 1,182 shares for $316,763.35
  • 07/28/2026: 3,580 shares for $909,571.97
  • 07/27/2026: 2,190 shares for $570,474.85

Market Impact & Significance

Trading significance is rated as Low. The proposed transaction represents less than 0.001% of Natera's 144,144,170 outstanding shares. Given that this sale is part of an established Rule 10b5-1 trading program adopted months in advance, it reflects routine insider liquidity and tax management following RSU vestings rather than an ad-hoc sentiment shift on the company's operational trajectory.

Topics:#NTRA#Natera#Form144#InsiderSelling#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.